1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Shanghai No.1 Pharmacy Co., Ltd.

Shanghai No.1 Pharmacy Co., Ltd.

600833.SS
Shanghai No.1 Pharmacy Co., Ltd.CN flagShanghai Stock Exchange
9.75
CNY
-0.02
- -
2.18BMarket Cap
Shanghai No.1 Pharmacy Co., Ltd.
600833.SS
(Shanghai Stock Exchange)

Recent

price

9.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.3
5.52
5.96
5.9
6.5
6.52
6.93
6.8
5.24
5.62
7.18
6.22
11.84
8.15
8.57
9.59
9.03
Revenue per Share
0.14
0.16
0.16
0.15
0.17
0.18
0.21
0.19
0.21
0.24
0.31
0.22
0.64
0.4
0.73
0.26
0.21
Basic EPS, GAAP
0.14
0.07
0.01
- -
0.07
0.19
0.15
0.47
0.15
0.43
0.33
0.11
0.54
0.2
-0.01
0.33
-0.09
Free Cash Flow per Basic Share
0.07
0.03
0.05
0.05
0.05
0.05
0.06
0.07
0.06
0.07
0.08
0.1
0.12
0.22
0.13
0.23
0.01
Dividend per Share
1.04
1.13
1.23
1.31
1.47
1.52
1.71
1.75
1.92
2.11
2.31
2.37
2.94
3.05
3.61
3.63
3.45
Book Value per Share
1.66
1.55
1.89
2.05
2.7
3.16
3.08
2.87
2.76
3.08
3.16
3.26
4.08
4.33
4.95
5.11
4.82
Tangible Book Value per Share
217
230
228
228
218
229
219
229
225
221
221
225
224
223
223
222
224
Basic Weighted Avg Shares
1,147
1,268
1,358
1,348
1,415
1,491
1,519
1,556
1,177
1,243
1,587
1,398
2,656
1,820
1,915
2,130
2,019
Sales/Revenue/Turnover
3.64
3.91
3.76
2.86
2.96
2.69
2.8
3.08
1.05
3.23
3.69
1.07
8.69
1.23
-0.36
0.4
-0.16
Operating Margin (%)
9
9
11
9
11
9
9
9
10
9
8
45
48
54
66
70
- -
Depreciation Expense
30
37
36
34
37
41
46
43
47
53
69
49
144
89
163
58
47
Net Income, GAAP
26.63
29.35
31.42
23.69
25.65
24.53
20.93
24.22
20.04
22.64
24.39
24.25
24.65
24.03
24.35
23.03
23.97
Effective Tax Rate (%)
2.64
2.9
2.68
2.54
2.62
2.76
3.03
2.79
4.01
4.27
4.32
3.53
5.41
4.91
8.51
2.71
2.34
Profit Margin (%)
142
179
179
207
246
281
317
344
382
427
245
219
471
440
479
391
427
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
89
63
88
107
116
108
92
LT Debt
436
429
500
536
651
783
736
714
674
732
747
778
959
1,008
1,144
1,171
1,115
Total Equity
7.1
7.86
7.28
5.47
5.06
4.09
4.3
4.87
1.37
4.33
4.95
1.17
15.03
1.27
-0.39
0.47
-0.18
Return on Invested Capital (%)
12.38
13.51
12.68
10.55
9.79
10.14
10.45
9.35
9.63
11.39
10.77
7.07
17.45
9.16
16.38
5.68
4.96
Return on Capital (%)
13.84
15.16
13.55
11.86
11.95
12.32
12.73
11.22
11.35
11.82
14.01
9.46
24.06
13.3
21.93
7.17
6.09
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
160
123
110
LT Borrowings
- -
- -
- -
LT Finance Leases
116
104
92
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
223
223
223
Market Capitalization
3,012
2,790
2,839

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,127
1,201
1,156
Cash, Cash Equivalents & STI
452
456
390
Accounts Receivable, Net
189
170
158
Inventories
336
382
425
Total Current Liabilities
648
663
728
Payables & Accruals
- -
- -
- -
ST Debt
160
123
110
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.44%
9.66%
2.31%
Free Cash Flow
-215.48%
-487.48%
-2,606.58%
Net Income, GAAP
19.92%
28.57%
-64.59%
Sales/Revenue/Turnover
7.63%
12.61%
11.23%
Total Cash Common Dividend
21.11%
30.85%
72.68%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
462
431
476
546
1,915
2025
504
493
591
- -
2,130
2026
485
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
- -
- -
- -
0.73
2025
0.02
- -
- -
- -
0.26
2026
0.1
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.13
2025
- -
- -
- -
- -
0.23
2026
- -
- -
- -
- -
- -
Similar Companies
Panjon Ltd. (PANJON.BO)
Pharmarise Holdings Corporation (2796.T)
Crestchem Limited (CRSTCHM.BO)
Relevium Technologies Inc. (RLLVF)
AXM Pharma, Inc. (AXMP)
Ohki Healthcare Holdings Co.,Ltd. (3417.T)
Business
Shanghai No.1 Pharmacy Co., Ltd. (600833.SS) engages primarily in the retail and wholesale of pharmaceutical products in China. The company offers Chinese and Western medicines, nutritional health products, medical equipment, Chinese herbal medicines and tablets, health convenience products, food, rehabilitation care items, contact lenses, cosmetics including brands such as LA ROCHE-POSAY, Avene, Vichy and Freeplus, and other commodities like Lei Shi Pearl Powder, Tongrentang Ejiao Powder and Wanshuntang Yangyin mouth fragrance mixture; it operates through flagship stores such as Shanghai Pharmacy Store, Coronary Pharmacy, century-old outlets including Wuzhou Pharmacy and Lao Deji Pharmacy, and subsidiaries like Shanghai Changcheng Huamei Instrument Chemical Co., Ltd.. Founded in 1992 and headquartered at No. 681 Xiaomuqiao Road, 20th Floor, Xuhui District, Shanghai, China, the company serves terminal medical institutions, pharmaceutical companies and end consumers primarily in East China, with select stores designated for medical insurance settlements and duty-free operations for departing customers. In recent developments, the company reported 2024 annual revenue of RMB1.915 billion, up 5.26% year-over-year, alongside a 2025 first-quarter business update and board resolutions; it maintains focus on store expansion, medical insurance qualifications and health sector diversification amid property expropriations in Shanghai's Huangpu District.